ArticleStem cell research & therapy2025
The role of ASS1 in mouse embryonic stem cell differentiation into mesendoderm lineages.
Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundArgininosuccinate synthase (ASS1) is a pivotal enzyme involved in the urea cycle, playing a crucial role in aspartate catabolism, arginine and nitric oxide biosynthesis. These biological processes are crucial for the growth and development of mammals. However, the functions of urea cycle-related genes in mouse embryonic stem cells (mESCs) remain largely unclear. Here, we investigated the impact of ASS1 knockout on the mESCs pluripotency and its role in determining cell fate.
methodsASS1 was knocked out in mESCs using CRISPR-Cas9. Changes in pluripotency post-knockout were analyzed via immunofluorescence, Western blotting, differentiation assays, and chimera formation. Cardiomyocyte differentiation assays evaluated the impact on cardiac lineage specification. RNA sequencing (RNA-seq), Western blotting, and signaling pathway inhibitors were used to investigate alterations in molecular signatures and regulatory mechanisms.
resultsASS1 knockout did not compromise mESCs pluripotency maintenance or self-renewal but perturbed the cell cycle. It upregulated mesendoderm markers while downregulating ectoderm markers. Notably, ASS1 deficiency enhanced cardiomyocyte differentiation potential. The multi-lineage differentiation markers were reversed by either ASS1 overexpression or treatment with Wnt/β-catenin inhibitors.
conclusionsASS1 knockout directs mESCs toward mesendoderm lineage commitment, thereby promoting beating cardiomyocyte generation. Thus, ASS1 acts as a regulatory switch whose absence drives mesendoderm differentiation and enhances cardiomyocyte production.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.